Klin Onkol 2006; 19(1): 30-32.
Summary: VEGF is the key mediator of angiogenesis, which is essential for tumour growth. VEGF is upregulated in most human cancers and is often linked to poor prognosis. The activity of VEGF is induced through binding to cell surface receptors, principally VEGF receptor-2. Bevacizumab is a recombinant, humanized monoclonal anti-VEGF antibody which prevents the interaction of VEGF with its receptors. Bevacizumab normalizes tumour vasculature, increases chemotherapy delivery, reduces microvascular growth, inhibits progression of primary and metastatic disease. In the following case report we present the significant antitumour activity of bevacizumab in combination with chemotherapy in a patient with locallly advanced metastatic liver involvement
